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24.9 years (SD 14.4). Comparing the use of symptomatic medication (rescue and 
daily), diagnostic-tests, unscheduled medical care (allergist and emergency vis-
its) and sick-leave days number associated with SCIT treatment versus no SCIT 
treatment. SCIT treatment vs no SCIT treatment costs ratio was performed: Used 
resources (Symptomatic medication, unscheduled medical care, diagnostic-tests, 
and 3 years SCIT treatment and sick-leave days) were quantified in € . Efficacy 
(decreased resource usage) of first year treatment was assumed during the remain-
ing two years and during a three years follow-up period. Results: After a single 
year of SCIT all quantified resources (emergency and allergist visits, diagnostic tests, 
rescue medication and work absence days) diminished significantly (p< 0.05) from 
baseline. Reductions in resources’ cost: Hospital resources (100% in Hospitalizations; 
82% in additional visits to the allergist; 79% in ER visits). In medication: (56% in 
rescue medication; 63% in daily medication). In diagnostic tests: (75% in spirometry 
testing broncho-dilation; 72% in O2 saturation measuring; 90% in FeNO measuring 
and 81% in chest radiographs. In leave sick days 94%. Ratio of comparative calcu-
lation described as SCIT treatment versus non SCIT treatment (or conventional 
symptomatic treatment) is 0.8. ConClusions: Considering 3 years of SCIT, and 3 
follow up years of sustained efficacy after completing treatment, cost per patient 
SCIT treated is estimated at 20% below to the cost non SCIT treated patient. Direct 
costs are reduced by 64% and indirect costs by 94%. SCIT of hypoallergenic prepara-
tion of dust-mite allows cost savings vs conventional treatment.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes & Patient 
Preference Studies
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objeCtives: Improving asthma control has more recently focused on potentially 
modifiable clinical and behavioural characteristics including correct inhaler tech-
nique, treatment of concomitant allergic rhinitis (AR), adherence and smoking. 
This research aimed to establish the relationship of these factors with measures 
of asthma control and overall health status to add to the growing body of evi-
dence helping to optimize asthma management interventions. Methods: Data 
were drawn from the USA 2013 Respiratory Disease Specific Programme, a cross-
sectional survey of adult asthma patients consulting for routine care. Partial Least 
Squares Path Modelling was used to quantify the inner model relationships between 
latent variables of patient-reported satisfaction of drug delivery, device functionality, 
device feedback (based on groupings of 12 inhaler device attributes), concomitant 
AR, adherence (Morisky Medication Adherence Scale), smoking history (smok-
ing status, years smoked, number smoked per day), patient reported outcomes 
(Asthma Control Test, Jenkins Sleep Questionnaire, EuroQol-5D-3L) and physician-
reported number of asthma exacerbations in the last 12 months. Patients not receiv-
ing inhaled maintenance therapy were excluded. Results: 243 patients met the 
inclusion criteria. All manifest variable loadings were positive, and a minimum 
Cronbach’s Alpha of 0.713 for the latent variables indicated unidimensionality of 
the manifest variables for each of the latent variables. Cross-loadings were also 
supportive of the hypothesised outer model. Better patient outcomes were sig-
nificantly associated with patient satisfaction with drug delivery (p= 0.002), adher-
ence (p= 0.049), negative smoking history (p< 0.001) and absence of concomitant 
AR (p= 0.005). The R2 value for outcomes was 13.3%, and the pseudo goodness of 
fit, which measures the overall prediction performance of the path model, was 
19.5%. ConClusions: Improving patient satisfaction with inhaler drug delivery 
represents one potentially modifiable aspect of asthma management alongside 
appropriate treatment of AR, smoking cessation and improving adherence, which 
are likely to have a positive impact on asthma patient outcomes.
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objeCtives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with Chronic Obstructive Pulmonary Disease and 
the influence of patient´ preference. Methods: Design: Multicenter patients´ pref-
erence trial or comprehensive cohort design ISRCTN15106246. Patients: 465 COPD 
patients (to detect a difference between groups of 25%, 80% statistical power, 95% 
confidence level, 40% expected losses), with inhaled treatment, written consent. 
Non-probabilistic consecutive sampling. Allocation: Patients without strong pref-
erences for a treatment were randomised: RCT group (block randomization), and 
those with strong preferences were given their choice: PPS group. Variables: Primary 
outcomes: Performance of correct inhalation technique. Secondary outcomes: Pick flow, 
Baseline dyspnea index (BDI), Functional status (forced spirometry). Interventions: 
Intervention-A: Written information. A leaflet with the correct inhalation technique 
for the main inhaler devices used in our area. Intervention-B: Intervention-A + indi-
vidual training (by instructors). Follow-up: 12 month, visits: baseline, 1 month, 3rd 
month, 6th month, 12th month. Statiscal analysis: Mean, frequency, 95% confidence 
interval at baseline. Number Needed to Treat for a benefit (NNT) was calculated. 
Intention to treat analysis. Results: Predominance of males (91.4%), mean age 
69.8 years (CI95%, 69.00-70.59); FEV1 (mean)= 55.91% (IC95%, 53.62-58.2), mixed res-
piratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticoster-
compared with Symbicort® Turbuhaler®was based on a conservative assump-
tion. Results: An estimated 167,666 adult patients used Symbicort® Turbuhaler® 
annually in Sweden and were therefore eligible for treatment with DuoResp® 
Spiromax®, with 72,935 of these exhibiting poor inhalation technique. Based on 
the predicted improvement in inhalation technique with DuoResp® Spiromax® 
compared with Symbicort® Turbuhaler® – and assuming a hypothetical uptake of 
DuoResp® Spiromax®reaching 25% in years 4 and 5 – estimated societal cost savings, 
through the avoidance of 147,158 lost productive days, totalled SEK285.4 million 
(€ 31.2 million). ConClusions: DuoResp® Spiromax® has the potential to improve 
inhalation technique compared with Symbicort® Turbuhaler®, which would likely 
result in substantial societal cost savings.
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objeCtives: Increased health care resource utilisation (HCRU) is associated with 
inadequately controlled asthma. Here, we evaluate the impact of omalizumab 
on HCRU in patients with moderate or severe persistent asthma. Methods: A 
retrospective case-crossover study was conducted using the Truven MarketScan 
database. Data between 1-January-2007 to 30-September-2012 was collected for 
analysis. Patients included in the analysis had to have a diagnosis of moderate or 
severe persistent asthma, be ≥ 12 years of age during the analysis period, have had 
2 years of continuous enrolment (1 year pre/post omalizumab index date), and have 
had exposure to omalizumab continuously for ≥ 12 months. All-cause and asthma-
related HCRU during the years, pre and post omalizumab initiation, were compared 
using McNemar tests and 2-sided paired Student’s t test. Data were stratified by 
asthma severity based on NHLBI criteria. Results: A total of 429 patients (mean 
age, 46.6 years; female, 59.0%; Moderate= 340 [79.3%], Severe= 89 [20.7%]) from the 
database were included in the analysis. The use of omalizumab was associated with 
49.3% (p= 0.0003), 54.0% (p= 0.001), and 35.3% (p= 0.1466) reductions in the mean 
number of asthma-related ER visits and 69.2% (p= 0.0005), 65.5% (p= 0.0045), and 
80.0% (p= 0.0449) reduction in the mean number of asthma-related hospitalisations 
among All, Moderate, and Severe asthma patients, respectively. The mean length of 
stay for asthma-related hospitalisations was also reduced to 71.2% (p= 0.0002), 64.5% 
(p= 0.0016), and 90.6% (p= 0.0442) in All, Moderate, and Severe patients respectively. 
All-cause ER visits were reduced by 30.8% (p= 0.0014), 32.5% (p= 0.0045), and 25.0% 
(p= 0.1348), and hospitalisation reduced by 48.9%, 45.2%, and 64.7% (all p≤ 0.0155) in 
All, Moderate, and Severe asthma patients respectively. Cohort analysis of severe 
asthmatics was limited by sample size. ConClusions: In patients with moderate 
persistent asthma, omalizumab use was associated with significant reductions in 
all-cause and asthma-related HCRU.
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objeCtives: Correct device technique has a significant influence on the delivery 
of inhaled therapies and can thus impact the control and management of asthma. 
The objective of this literature review was to examine the impact of device handling 
errors on QOL and health care resources to understand the potential value of a 
novel inhaler device for health care systems and patients. Methods: A literature 
search of articles published 2009–2013 was undertaken using MeSH terms and key 
words in MEDLINE®, supplemented by a grey literature review and searching of 
reference lists. Article selection and relevant data extraction were based on key 
words relating to handling error, QOL, and health care resource use. Results: Of 
575 potentially relevant publications, 22 were selected for in-depth review. Papers 
reported 25–73% of patients make critical handling errors that lead to no-dose or 
reduced-dose delivery on first use of devices. Incorrect inhaler use was four times 
more frequently reported in patients with uncontrolled asthma than in patients 
with controlled asthma. Poor asthma control also impacts resource use: poorly-
controlled patients made twice as many ER visits, and spent 2–3 times more time 
consulting with physicians than controlled patients (either physician visits or 
time speaking to physicians). Asthma control also impacts QOL: poorly-controlled 
patients reported health-state utility (EQ-5D) values of 0.52–0.69, compared to 0.88–
0.93 for well-controlled patients. ConClusions: Handling errors with devices can 
lead to poorly-controlled patients, resulting in reduced QOL and increased health 
care resource use. New inhaler devices represent an opportunity to reduce errors 
and improve asthma control, therefore improving QOL and reducing resource use. 
Further research is required to model the relationship between a reduction in han-
dling error and improved asthma control status, and the subsequent impact on 
resource use and QOL.
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objeCtives: Quantifying cost difference between conventional symptomatic treat-
ment of mite allergy and subcutaneous specific immunotherapy (SCIT) with high 
doses of hypoallergenic dust-mite preparation. Methods: Observational, retro-
spective and multicenter study carried out in Spain in 2013.419 patients diagnosed 
with rhinitis and / or bronchial asthma for mite allergy were retrieved. Mean age 
